Analysis patient adherence to the antineoplastic oral therapy treatement in the chemotherapy pharmacy at hospital of Mato Grosso do Sul

Breast cancer is the leading cause of death due to neoplasm in the female gender. Adjuvant hormone therapy is an important ally in breast cancer treatment because it improves survival and decreases the recurrence of neoplasm. Tamoxifen has been widely used in patients with breast cancer who present...

Full description

Bibliographic Details
Main Authors: Fabiana Mesquita Roese, Eliane Moro Fontana, Karen Carla de Brito Pereira
Format: Article
Language:English
Published: Centro Universitário ENIAC 2018-01-01
Series:Revista Eniac Pesquisa
Subjects:
Online Access:https://ojs.eniac.com.br/index.php/EniacPesquisa/article/view/499
_version_ 1818247868573548544
author Fabiana Mesquita Roese
Eliane Moro Fontana
Karen Carla de Brito Pereira
author_facet Fabiana Mesquita Roese
Eliane Moro Fontana
Karen Carla de Brito Pereira
author_sort Fabiana Mesquita Roese
collection DOAJ
description Breast cancer is the leading cause of death due to neoplasm in the female gender. Adjuvant hormone therapy is an important ally in breast cancer treatment because it improves survival and decreases the recurrence of neoplasm. Tamoxifen has been widely used in patients with breast cancer who present positive estrogen receptor (ER) for up to 5 years. Patient treatment acceptance is an important component of pharmaceutical care. This study aims to analyze patient adherence to the antineoplastic oral therapy treatment in the chemotherapy pharmacy at Regional Hospital of Mato Grosso do Sul. This is a retrospective descriptive observational study from July to December 2016, conducted with patients older than 18 years (n = 95) using hormone therapy with Tamoxifen. Results: It was observed that most of the patients were in the age range of 42-60 years, single, white and coming from Campo Grande. In the study, 30.5% of the patients stopped withdrawing the medication in any of the evaluated months. The participation of the pharmacist jointly the multidisciplinary team and the patient is essential in managing side effects, adverse reactions and promotion of adherence.Breast cancer is the leading cause of death due to neoplasm in the female gender. Adjuvant hormone therapy is an important ally in breast cancer treatment because it improves survival and decreases the recurrence of neoplasm. Tamoxifen has been widely used in patients with breast cancer who present positive estrogen receptor (ER) for up to 5 years. Patient treatment acceptance is an important component of pharmaceutical care. This study aims to analyze patient adherence to the antineoplastic oral therapy treatment in the chemotherapy pharmacy at Regional Hospital of Mato Grosso do Sul. This is a retrospective descriptive observational study from July to December 2016, conducted with patients older than 18 years (n = 95) using hormone therapy with Tamoxifen. Results: It was observed that most of the patients were in the age range of 42-60 years, single, white and coming from Campo Grande. In the study, 30.5% of the patients stopped withdrawing the medication in any of the evaluated months. The participation of the pharmacist jointly the multidisciplinary team and the patient is essential in managing side effects, adverse reactions and promotion of adherence.
first_indexed 2024-12-12T15:11:33Z
format Article
id doaj.art-82ea33e83b7444c0b9bdef7493bfd8ed
institution Directory Open Access Journal
issn 2316-2341
language English
last_indexed 2024-12-12T15:11:33Z
publishDate 2018-01-01
publisher Centro Universitário ENIAC
record_format Article
series Revista Eniac Pesquisa
spelling doaj.art-82ea33e83b7444c0b9bdef7493bfd8ed2022-12-22T00:20:37ZengCentro Universitário ENIACRevista Eniac Pesquisa2316-23412018-01-017112514110.22567/rep.v7i2.499358Analysis patient adherence to the antineoplastic oral therapy treatement in the chemotherapy pharmacy at hospital of Mato Grosso do SulFabiana Mesquita RoeseEliane Moro FontanaKaren Carla de Brito PereiraBreast cancer is the leading cause of death due to neoplasm in the female gender. Adjuvant hormone therapy is an important ally in breast cancer treatment because it improves survival and decreases the recurrence of neoplasm. Tamoxifen has been widely used in patients with breast cancer who present positive estrogen receptor (ER) for up to 5 years. Patient treatment acceptance is an important component of pharmaceutical care. This study aims to analyze patient adherence to the antineoplastic oral therapy treatment in the chemotherapy pharmacy at Regional Hospital of Mato Grosso do Sul. This is a retrospective descriptive observational study from July to December 2016, conducted with patients older than 18 years (n = 95) using hormone therapy with Tamoxifen. Results: It was observed that most of the patients were in the age range of 42-60 years, single, white and coming from Campo Grande. In the study, 30.5% of the patients stopped withdrawing the medication in any of the evaluated months. The participation of the pharmacist jointly the multidisciplinary team and the patient is essential in managing side effects, adverse reactions and promotion of adherence.Breast cancer is the leading cause of death due to neoplasm in the female gender. Adjuvant hormone therapy is an important ally in breast cancer treatment because it improves survival and decreases the recurrence of neoplasm. Tamoxifen has been widely used in patients with breast cancer who present positive estrogen receptor (ER) for up to 5 years. Patient treatment acceptance is an important component of pharmaceutical care. This study aims to analyze patient adherence to the antineoplastic oral therapy treatment in the chemotherapy pharmacy at Regional Hospital of Mato Grosso do Sul. This is a retrospective descriptive observational study from July to December 2016, conducted with patients older than 18 years (n = 95) using hormone therapy with Tamoxifen. Results: It was observed that most of the patients were in the age range of 42-60 years, single, white and coming from Campo Grande. In the study, 30.5% of the patients stopped withdrawing the medication in any of the evaluated months. The participation of the pharmacist jointly the multidisciplinary team and the patient is essential in managing side effects, adverse reactions and promotion of adherence.https://ojs.eniac.com.br/index.php/EniacPesquisa/article/view/499Adesão à medicaçãoModulador Seletivo dos Receptores de EstrógenoNeoplasia da MamaAtenção Farmacêutica.
spellingShingle Fabiana Mesquita Roese
Eliane Moro Fontana
Karen Carla de Brito Pereira
Analysis patient adherence to the antineoplastic oral therapy treatement in the chemotherapy pharmacy at hospital of Mato Grosso do Sul
Revista Eniac Pesquisa
Adesão à medicação
Modulador Seletivo dos Receptores de Estrógeno
Neoplasia da Mama
Atenção Farmacêutica.
title Analysis patient adherence to the antineoplastic oral therapy treatement in the chemotherapy pharmacy at hospital of Mato Grosso do Sul
title_full Analysis patient adherence to the antineoplastic oral therapy treatement in the chemotherapy pharmacy at hospital of Mato Grosso do Sul
title_fullStr Analysis patient adherence to the antineoplastic oral therapy treatement in the chemotherapy pharmacy at hospital of Mato Grosso do Sul
title_full_unstemmed Analysis patient adherence to the antineoplastic oral therapy treatement in the chemotherapy pharmacy at hospital of Mato Grosso do Sul
title_short Analysis patient adherence to the antineoplastic oral therapy treatement in the chemotherapy pharmacy at hospital of Mato Grosso do Sul
title_sort analysis patient adherence to the antineoplastic oral therapy treatement in the chemotherapy pharmacy at hospital of mato grosso do sul
topic Adesão à medicação
Modulador Seletivo dos Receptores de Estrógeno
Neoplasia da Mama
Atenção Farmacêutica.
url https://ojs.eniac.com.br/index.php/EniacPesquisa/article/view/499
work_keys_str_mv AT fabianamesquitaroese analysispatientadherencetotheantineoplasticoraltherapytreatementinthechemotherapypharmacyathospitalofmatogrossodosul
AT elianemorofontana analysispatientadherencetotheantineoplasticoraltherapytreatementinthechemotherapypharmacyathospitalofmatogrossodosul
AT karencarladebritopereira analysispatientadherencetotheantineoplasticoraltherapytreatementinthechemotherapypharmacyathospitalofmatogrossodosul